Seattle Genetics ( SGEN) Awaiting an FDA announcement on Aug. 30 on the approval (or not) of the company's lymphoma drug Adcetris. Year to date performance: Flat Performance since June 30: -26% It looks like hedge funds were selling Seattle Genetics, perhaps because the stock's valuation ran up significantly ahead of the FDA's drug approval decision. Healthcor Management, Renaissance Technologies and Moore Capital Management were among the funds lightening their Seattle Genetics's positions in the second quarter. Citadel Advisors and Fortis Investments both added relatively small amounts of shares to existing positions. Baker Brothers kept its big 19.28 million-share stake in Seattle Genetics stable during the quarter.